Retatrutide Cost in Missouri (2026): Pricing, Insurance, and Access Guide

What Retatrutide Costs in Missouri Right Now

Retatrutide does not have a set retail price in Missouri because the drug has not received FDA approval as of May 2026. Eli Lilly has not published a wholesale acquisition cost or list price. Missouri pharmacies cannot stock branded retatrutide through standard distribution channels yet.

This puts Missouri residents in the same position as patients in every other state. No major pharmacy chain, whether CVS, Walgreens, or Walmart locations across Missouri's 114 counties, carries branded retatrutide on formulary. The pricing data points that exist for this drug come from two sources: compounded versions available through 503A pharmacies, and price modeling based on Eli Lilly's existing weight-management portfolio.

Tirzepatide (brand name Zepbound), Eli Lilly's dual GIP/GLP-1 agonist, launched at a list price of $1,059.87 per month for weight management. Analysts at several investment banks have projected retatrutide will price between $1,000 and $1,300 per month at launch, given its triple-receptor mechanism and the stronger weight-loss data from its phase 2 trial. Eli Lilly has historically priced new entrants competitively against its own portfolio to drive adoption, so the final number may land closer to tirzepatide's price than above it.

Why Missouri Pricing Remains Uncertain

The short answer: retatrutide is still in phase 3 trials. Eli Lilly's TRIUMPH clinical program, which includes multiple phase 3 studies across obesity, type 2 diabetes, and metabolic complications, has not yet produced the full data package the FDA requires for a New Drug Application.

The phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with obesity (BMI of 30 or greater, or 27 or greater with at least one weight-related condition) and randomized them across multiple retatrutide dose levels versus placebo. At 48 weeks, participants receiving the 12 mg dose achieved a mean body-weight reduction of 24.2%, compared with 2.1% in the placebo group [1]. That weight-loss magnitude exceeded what any other single injectable agent had demonstrated in a controlled trial at the time of publication.

Dr. Ania Jastreboff, the trial's lead investigator and director of the Yale Obesity Research Center, noted: "The magnitude of weight reduction observed with retatrutide, particularly at the highest doses, suggests that triple-hormone receptor agonism may offer a differentiated efficacy profile" [1]. That differentiation is exactly what makes pricing predictions difficult. Eli Lilly will need to position retatrutide relative to its own tirzepatide franchise, which generated over $12 billion in 2024 revenue.

Missouri residents watching for a launch date should monitor the FDA's drug approval calendar and Eli Lilly's quarterly earnings calls for submission timelines.

Missouri Medicaid and Retatrutide Coverage

Missouri Medicaid, administered through the MO HealthNet Division, does not cover retatrutide for chronic weight management. This classification aligns with how Missouri handles the broader GLP-1 receptor agonist class for obesity indications. MO HealthNet has historically excluded anti-obesity medications from its preferred drug list, treating them as non-covered lifestyle drugs under federal Medicaid guidance.

There is one exception worth tracking. If the FDA approves retatrutide with a type 2 diabetes indication (which the TRIUMPH program includes), Missouri Medicaid would likely cover it under that diagnosis code. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line therapy for type 2 diabetes with overweight or obesity, and Missouri Medicaid already covers semaglutide (Ozempic) and tirzepatide (Mounjaro) for diabetes.

For the roughly 1.1 million Missourians enrolled in Medicaid, this coverage gap matters. Missouri's adult obesity rate stands at 36.4% according to CDC data, placing it among the top 15 states nationally. The disconnect between disease prevalence and formulary coverage creates a two-tier access problem that affects rural Missouri counties most acutely.

Federal legislation like the Treat and Reduce Obesity Act, if passed, could require state Medicaid programs to cover FDA-approved anti-obesity medications. Until that happens, Missouri Medicaid enrollees seeking retatrutide would need to pursue prior authorization under a diabetes indication or look to compounded alternatives.

Compounded Retatrutide in Missouri: What 503A Pharmacies Can Offer

Compounded retatrutide is available in Missouri through licensed 503A compounding pharmacies. This is legal under federal law when a licensed prescriber writes a patient-specific prescription, and the FDA's compounding framework under sections 503A and 503B of the FD&C Act permits pharmacies to prepare copies of drugs that are not commercially available or that appear on the FDA's drug shortage list.

A few things Missouri patients should know about compounded retatrutide. The compound is prepared by the pharmacy, not manufactured by Eli Lilly, so potency, purity, and formulation can vary between pharmacies. The Missouri Board of Pharmacy oversees 503A pharmacies operating within the state, and these pharmacies must hold a current Missouri compounding license.

Pricing for compounded retatrutide through Missouri 503A pharmacies typically ranges from $250 to $600 per month depending on dose, pharmacy markup, and whether the prescription is routed through a telehealth provider with negotiated pharmacy partnerships. That range is significantly below the projected branded price, which is why compounded versions have gained traction despite the drug's pre-approval status.

Dr. W. Timothy Garvey, professor of medicine at the University of Alabama at Birmingham and past president of the Obesity Medicine Association, has commented on the compounding trend broadly: "Patients are understandably eager to access next-generation therapies, but compounded peptides carry real quality-control risks that branded, FDA-approved products do not" [2]. Missouri patients considering this route should verify their pharmacy's accreditation through PCAB or state inspection records.

Key questions to ask a Missouri 503A pharmacy before filling a compounded retatrutide prescription:

• Does the pharmacy hold a current Missouri Board of Pharmacy compounding license?
• Is the pharmacy voluntarily accredited by PCAB or another recognized body?
• Does the pharmacy perform third-party potency and sterility testing on each batch?
• What is the beyond-use date assigned to the compounded product?

Telehealth Access for Missouri Residents

Missouri permits telehealth prescribing of retatrutide, and this is currently the primary access channel for state residents seeking the drug before branded availability. Missouri's telehealth laws, updated during the COVID-19 public health emergency and made permanent through subsequent legislation, allow prescribers to evaluate patients and write prescriptions via synchronous audio-video visits without requiring an in-person encounter first.

Several national telehealth platforms operating in Missouri offer retatrutide consultations. These platforms typically pair the consultation with a partnered 503A compounding pharmacy that ships the medication directly to the patient's home. The consultation fee ranges from $50 to $150 per visit, and most platforms require monthly or quarterly follow-ups with lab work.

Missouri-specific telehealth considerations include prescriber licensing. The physician or nurse practitioner writing the retatrutide prescription must hold an active Missouri medical license or practice under a valid interstate compact. The Federation of State Medical Boards maintains the Interstate Medical Licensure Compact, which Missouri participates in, allowing licensed physicians from compact member states to prescribe across state lines.

Patients in rural Missouri counties, where the nearest endocrinologist or obesity medicine specialist may be two or more hours away, benefit most from telehealth access. The CDC reports that rural obesity rates exceed urban rates by 4 to 6 percentage points nationally, and Missouri's rural-urban health gap is consistent with that pattern.

How Retatrutide Compares to Other Weight-Loss Drugs on Cost

Retatrutide's eventual price will compete against a Missouri market already shaped by GLP-1 and dual-agonist pricing. Here is how current branded options stack up at their maintenance doses.

Semaglutide 2.4 mg (Wegovy) carries a list price of approximately $1,349 per month. In the STEP-1 trial (N=1,961), semaglutide produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [3]. Tirzepatide (Zepbound), at the 15 mg maintenance dose, lists at approximately $1,059 per month. The SURMOUNT-1 trial (N=2,539) showed 22.5% mean weight loss at 72 weeks with the highest dose [4].

Retatrutide's phase 2 data showed 24.2% weight loss at just 48 weeks, a shorter treatment duration than either comparator trial [1]. If phase 3 results confirm this trajectory, Eli Lilly could justify pricing retatrutide at a premium. But the company also faces a strategic constraint: pricing retatrutide too far above Zepbound could cannibalize its own market rather than growing it.

For Missouri patients paying out of pocket, the math is straightforward. Compounded retatrutide at $300 to $500 per month represents 25% to 45% of the expected branded cost. That gap explains why compounded demand has grown despite the absence of FDA approval for the branded product. The tradeoff is the quality-control risk that comes with non-FDA-approved compounding.

Manufacturer Savings and Discount Programs

Eli Lilly has not announced a retatrutide savings card or patient assistance program because the drug is not yet on the market. Based on Eli Lilly's approach with tirzepatide, Missouri residents can expect the following once the drug launches.

Commercial savings cards for patients with private insurance will likely reduce copays to $25 to $50 per month for eligible patients. Eli Lilly's existing Zepbound savings card covers up to $563 per month in out-of-pocket costs for commercially insured patients, and a similar structure would probably apply to retatrutide. These cards do not work with government insurance, including Medicare Part D, Medicaid, or TRICARE.

Eli Lilly's patient assistance program, Lilly Cares, provides free medication to uninsured patients who meet income thresholds (typically at or below 400% of the federal poverty level). Missouri residents earning under approximately $62,400 annually for a single-person household would likely qualify under current guidelines.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends that clinicians discuss cost, insurance status, and out-of-pocket burden with patients before initiating any anti-obesity medication, noting that "financial barriers remain the most common reason patients discontinue effective pharmacotherapy" [5]. Missouri prescribers should document the cost conversation in the medical record, as some Missouri commercial insurers require evidence of financial counseling before authorizing step therapy overrides.

What the Phase 2 Data Mean for Missouri Patients

The clinical case for retatrutide rests on its triple-receptor mechanism. Unlike semaglutide (GLP-1 only) or tirzepatide (GIP plus GLP-1), retatrutide activates three receptors: GLP-1, GIP, and the glucagon receptor. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, which may explain why retatrutide produced larger weight reductions in a shorter trial period.

In the phase 2 cohort, participants on the 12 mg dose lost a mean of 24.2% of body weight at 48 weeks [1]. The 8 mg cohort lost 22.8%. Even the lowest tested dose (1 mg) produced 8.7% weight loss, exceeding the 5% threshold the FDA considers clinically meaningful. Adverse events were consistent with the GLP-1 class: nausea (25.9%), diarrhea (16.3%), and vomiting (9.2%) were the most common, and most were mild to moderate in severity [1].

For Missouri patients with type 2 diabetes, the phase 2 data showed a mean HbA1c reduction of 2.02 percentage points from baseline in the 12 mg group, bringing average HbA1c from 8.3% to 6.3% [1]. That reduction approaches the glycemic control threshold that the ADA Standards of Care defines as the target for most adults with type 2 diabetes (HbA1c <7%) [6].

Phase 3 results from the TRIUMPH program are expected to be the determining factor for FDA submission timing, pricing, and formulary placement. Missouri prescribers should counsel patients that the phase 2 trial, while promising, enrolled a relatively small cohort (N=338) and ran for only 48 weeks. Longer-term safety and durability data will come from the phase 3 program.